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A collection of randomly generated temperature-sensitive (ts) vaccinia virus (strain IHD-W) mutants were reported by S.
Dales et al., (1978, Virology, 84, 403–428) in 1978 and characterized by electron microscopy. We have performed further
genetic analysis on the Dales collection of mutants to make the mutants more useful to the scientific community. We obtained
the entire Dales collection, 97 mutants, from the American Type Culture Center (ATCC). All 97 mutants were grown and
reassessed for temperature sensitivity. Of these, 16 mutants were either very leaky or showed unacceptably high reversion
indices even after plaque purification and therefore were not used for further analysis. The remaining 81 ts mutants were
used to perform a complete complementation analysis with each other and the existing Condit collection of ts vaccinia virus
(strain WR) mutants. Twenty-two of these 81 Dales mutants were dropped during complementation analysis due to erratic or
weak behavior in the complementation test. Of the 59 mutants that were fit for further investigation, 30 fall into 13 of Condit’s
existing complementation groups, 5 comprise 3 previously identified complementation groups independent of the Condit
collection, and 24 comprise 18 new complementation groups. The 59 mutants which were successfully characterized by
complementation will be accessioned by and made available to the scientific community through the ATCC. © 2003 ElsevierKey Words: temperature-sensitive; complementation; IHD
INTRODUCTION
Poxviruses are large double-stranded DNA viruses
that replicate in the cytoplasm of host cells. In an effort to
understand the replication of these viruses, several
groups have isolated randomly generated, temperature-
sensitive (ts) virus mutants (Padgett and Tomkins, 1968;
Dales et al., 1978; Chernos et al., 1978; Condit and
Motyczka, 1981; Ensinger, 1982; Condit et al., 1983; Dril-
lien and Spehner, 1983; reviewed in Condit and Niles,
1990). Many of these conditional–lethal mutants were
sorted into complementation groups and assigned to
physical map positions using marker rescue. Some, for
example the Condit collection, have been systematically
subjected not only to complementation and physical
mapping analysis, but to phenotypic analysis as well.
The Condit collection comprises 63 mutants in 32
complementation groups of which 79% have been
mapped to individual genes. Phenotypic analysis of this
collection, based on protein synthesis and DNA replica-
tion, revealed four biochemical phenotypes. Mutants that
were indistinguishable from wt with respect to protein
and viral DNA synthesis at the permissive and nonper-
missive temperatures characterized the “normal” pheno-
1 These authors contributed equally to this work.© 2003 Elsevier Science (USA)
All rights reserved.
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type. Mutants that synthesized no viral DNA or late viral
proteins at the nonpermissive temperature characterized
the “DNA-negative” phenotype. Mutants that showed nor-
mal DNA synthesis and weak or delayed late viral protein
synthesis at the nonpermissive temperature character-
ized the “defective late” phenotype. Finally, the “abortive
late” phenotype was characterized by normal DNA syn-
thesis at the nonpermissive temperature and late viral
protein synthesis that began normally at the nonpermis-
sive temperature and then ceased abruptly (Condit and
Motyczka, 1981). The complete complementation and
partial physical mapping of the Condit collection has
made these mutants extremely useful and created a
major resource for vaccinia mutants.
Systematic genetic analysis of some other collections
has been more limited. For example, the Dales collection
of approximately 90 mutants was characterized and
grouped into 17 categories, A to Q, based on the pheno-
typic defects shown by electron microscopy (EM) at the
nonpermissive temperature (Table 1) (Dales et al., 1978).
These categories represent, in order of increasing com-
plexity, the stages of viral assembly reached during in-
fection at the nonpermissive temperature. However, in
the absence of complementation analysis, it is unclear
whether mutants possessing similar or different EM phe-
notypes represent mutations in the same or differentScience (USA)
2 To whom correspondence and reprint requests should be ad-
dressed. Fax: 352-392-3133. E-mail: condit@mgm.ufl.edu.
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0042-6822/03 $30.00genes. Nevertheless, the Dales collection is a rich re-
source of mutants. For example, it comprises a fascinat--W; ge
ing array of EM phenotypes (Szajner et al., 2001), and it
contains the only known ts mutations in the vaccinia
virus uracil glycosylase and in a subunit of the mRNA
capping enzyme (Carpenter and DeLange, 1991; Millns
et al., 1994). We therefore felt it would be of value to not
only conduct complementation analysis with the Dales
group but to also test the Dales mutants against the
Condit complementation groups to integrate the two col-
lections.
We have obtained the entire Dales collection of 97
vaccinia virus (strain IHD-W) mutants from the ATCC and
undertaken complementation analysis of this collection
to organize and categorize the mutants. The collection
was first verified for temperature sensitivity, allowing us
to identify those mutants that would work well in comple-
mentation analysis. Eighty-one mutants were selected
for complementation analysis with each other and with
the existing Condit collection of ts vaccinia virus (strain
WR) mutants. Complementation analysis eliminated 22
additional viruses due to erratic or weak complementa-
tion and revealed 18 new complementation groups in
addition to the 35 previously described by Condit et al.
(1983); Szajner et al. (2001), Millns et al. (1994), and
Carpenter and DeLange (1991). This analysis provides a
renewed source of useful ts mutants and increases the
number of genes covered. The purpose of this article is
to summarize the complementation analysis and compile
an accurate overview of ts mutants in vaccinia virus from
several collections including mutants isolated by Condit
and co-workers, some of the mutants isolated by Ens-
inger and co-workers, and the mutants isolated by Dales
and co-workers (Dales et al., 1978; Condit and Motyczka,
1981; Ensinger, 1982; Condit et al., 1983; Seto et al., 1987).
The assignment of the Dales mutants to the Condit
complementation groups is discussed and a description
of each of the Dales mutants currently available through
the ATCC is presented.
RESULTS AND DISCUSSION
Dales et al. (1978) originally grew and plaqued vac-
cinia IHD-W virus in L2 cells, a substrain of mouse L929
fibroblasts. Subsequently, all of the ts mutants were
isolated and characterized in this cell line as well. These
cells, as described by Dales et al., were not available
from ATCC. (The existing ATCC L2 cells are designated
as rat epithelial lung cells.) The Condit collection, con-
sisting of ts mutants in the vaccinia WR strain, were
isolated and characterized in African green monkey kid-
ney BSC40 cells (Condit and Motyczka, 1981). We there-
fore performed a preliminary experiment to compare the
growth and phenotype of the vaccinia IHD-W and WR
strains in BSC40 and L929 cells. The wild-type vaccinia
WR and IHD-W strains were grown in both BSC40 and
L929 cells at 37°C and were subsequently plaqued in both
BSC40 and L929 cells at 31, 37, and 39.5°C. Vaccinia strain
WR grew and plaqued better in BSC40 cells than in L929
cells. The IHD-W strain grew and plaqued equivalently in
BSC40 and L929 cells; however, the plaques were larger
on BSC40 cells (data not shown). In general, the BSC40
cells were easier to work with than L929 cells; they grew
faster and formed tighter monolayers. As a result of
these tests, we chose to perform all subsequent exper-
iments with BSC40 cells exclusively.
Dales et al. (1978) used a four-digit numbering system
to identify their mutants. In the course of working with the
mutants, we discovered that this system was extremely
cumbersome and prone to typographical error. In addi-
tion, we have found that the literature describing the
Dales mutants contains several errors attributable to this
numbering system. We therefore adopted a revised num-
bering system, which we propose to be used universally
in referring to vaccinia mutants (Tables 2-4, New system).
The nomenclature uses the first letter of the last name for
whom the collection is known, i.e., C for Condit, D for
Dales, and E for Ensinger. The mutants are then desig-
nated as temperature-sensitive (ts) and are listed se-
quentially (i.e., Dales mutants are (Dts)1–97) (Tables
2–4). All 97 mutants Dales mutants have been assigned
TABLE 1
Categories of Morphological Aberrations
Category Description
A No virus structure evident
B Foci of viroplasm
C Rudimentary virus membranes with spicules in foci
of viroplasm
D Foci of viroplasm and DNA paracrystals
E Foci of viroplasm, aberrant membranes without
spicules, and DNA paracrystals
F Aberrant membranes with spicules and viroplasm
G Incomplete membranes with spicules
H Composite of D–F as well as complete immature
particles
I Similar to G as well as complete immature
particles
J Composite of E, F, and I as well as dispersed
immature particles
K Granular foci and immature particles with
nucleoids but lacking internal dense material
L Immature particles with nucleoids and defective
membranes with spicules
M Immature particles without nucleoids and
intermediate maturing forms
N Factories containing immature and numerous
intermediate maturing forms
O Immature normal particles and mature particles
with aberrant cores
P Immature normal particles and mature particles
with cores that are predominantly lucent at the
center
Q Immature and mature particles of normal
appearance
Note. Table adapted from Dales et al. (1978).
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ATCC numbers (Tables 2–4, ATCC number). The 59 mu-
tants which were successfully characterized by comple-
mentation, plus Dts91 (see below), are being acces-
sioned by ATCC for distribution and can be obtained
once the accessioning is complete. The remaining 37
TABLE 2
Mutants That Were Assigned to Complementation Groups
New
system
Dales plaque
isolate no.
ATCC
number Purifieda
Dales EM
categoryb
Map
locationc
Dts2 155 VR-3110 P K U4
Dts4 260 VR-3130 P n.d. U5
Dts8 991 VR-3121 NP L U5
Dts9 1085 VR-3131 P E D13
Dts10 1131 VR-3142 NP C A24*
Dts11 1327 VR-3102 NP G,I F10
Dts12 1408 VR-3112 NP n.d. D5
Dts14 1655 VR-3132 NP B,P A24*
Dts15 1911 VR-3143 NP N B1
Dts16 1923 VR-3103 NP P U6
Dts17 1988 VR-3113 P n.d. U6
Dts18 2047 VR-3123 NP P U7
Dts19 2096 VR-3133 P B E11
Dts20 2160 VR-3144 NP P U8
Dts22 3145 VR-3114 P n.d. G2
Dts23 3268 VR-3124 NP n.d. E(2–8)
Dts25 3498 VR-3145 NP n.d. E(2–8)
Dts27 3578 VR-3115 P n.d. D4
Dts28 3679 VR-3125 NP G,P A24*
Dts30 4149 VR-3146 P DNA neg, B D4
Dts33 5752 VR-3126 NP P U9
Dts35 5804 VR-3147 P O U5
Dts36 6003 VR-3107 NP n.c. U10
Dts38 6389 VR-3127 NP DNA neg, C D5
Dts40 6567 VR-3148 P P U11
Dts41 6606 VR-3108 NP P E(2–8)
Dts42 6626 VR-3118 NP D G2
Dts44 6741 VR-3138 NP B J4
Dts45 6754 VR-3149 NP n.d. A30, G(6–8)*
Dts46 6757 VR-3109 NP F A30, G(6–8)*
Dts47 6828 VR-3119 NP P U12
Dts48 6937 VR-3129 P n.c. U13
Dts49 7004 VR-3140 NP G A24*
Dts50 7014 VR-3139 P n.d. U10
Dts52 7160 VR-3160 NP n.c. A24*
Dts56 7473 VR-3151 NP n.d. D5
Dts57 7526 VR-3161 P H U14
Dts60 7672 VR-3189 P n.d. A24
Dts61 7726 VR-3152 NP n.d. U15
Dts62 7743 VR-3162 P E D13
Dts66 7954 VR-3153 P n.c. A24
Dts67 8125 VR-3163 NP H,Q I8
Dts68 8490 VR-3173 P P G(6–8)
Dts71 8643 VR-3154 NP n.c. U16
Dts77 8933 VR-3165 P DNA neg, A, K U17
Dts78 8946 VR-3175 NP H,Q U18
Dts80 9021 VR-3193 NP H,Q E(2–8)
Dts82 9139 VR-3166 NP B U19
Dts83 9153 VR-3176 P J U20
Dts85 9174 VR-3194 NP C J6
Dts86 9179 VR-3157 NP n.c. A24*
Dts88 9203 VR-3177 NP E D13
Dts89 9231 VR-3186 NP C G(6–8)
Dts90 9235 VR-3195 P O A24*
Dts93 9281 VR-3178 P n.c. U5
Dts94 9283 VR-3187 P n.d. A24*
Dts95 9312 VR-3196 P n.d. U21
Dts96 9383 VR-3159 NP E,Q D12
Dts97 9609 VR-3169 NP B U8
a P/NP  plaque purified/not plaque purified.
b n.c. no category assigned by Dales. n.d. no description available.
c For mapping nomenclature, see footnote a, Table 6.
* Unusual complementation, see text.
TABLE 3
Mutants Eliminated During Complementation Analyses
New
system
Dales plaque
isolate no. ATCC number
Dales
categorya
Dts5 440 VR-3141 n.d.
Dts6 537 VR-3101 n.d.
Dts7 657 VR-3111 P
Dts13 1568 VR-3122 P
Dts24 3315 VR-3134 n.d.
Dts29 3681 VR-3135 I
Dts39 6501 VR-3137 H
Dts43 6712 VR-3128 G,P
Dts51 7133 VR-3150 M
Dts53 7221 VR-3170 I,P
Dts54 7316 VR-3179 Q
Dts55 7396 VR-3188 H
Dts69 8603 VR-3182 P
Dts70 8639 VR-3191 Q
Dts72 8697 VR-3164 G,P
Dts73 8741 VR-3174 DNA neg, B
Dts74 8743 VR-3183 H
Dts79 8987 VR-3184 n.c.
Dts81 9038 VR-3156 F
Dts87 9189 VR-3167 B
Dts91 9251 VR-3158 E,Q
Dts92 9276 VR-3168 P
a n.c. no category assigned by Dales. n.d. no description available.
TABLE 4
Mutants Not Tested in Complementation Analyses Because of
High Leakiness and High RI
New
system
Dales plaque
isolate no.
ATCC
number
Dales
categorya
Dts1 27 VR-3100 M
Dts3 203 VR-3120 n.c.
Dts21 3060 VR-3104 n.d.
Dts26 3564 VR-3105 n.d.
Dts31 4213 VR-3106 n.d.
Dts32 5730 VR-3116 n.d.
Dts34 5796 VR-3136 n.c.
Dts37 6007 VR-3117 n.d.
Dts58 7565 VR-3171 H
Dts59 7634 VR-3180 n.d.
Dts63 7790 VR-3172 DNA neg, A
Dts64 7800 VR-3181 n.d.
Dts65 7883 VR-3190 H
Dts75 8788 VR-3192 n.c.
Dts76 8880 VR-3155 n.d.
Dts84 9170 VR-3185 J
a n.c. no category assigned by Dales. n.d. no description available.
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Dales mutants will be archived by ATCC. In addition to
simplifying the nomenclature, the new system has the
advantage of resetting the references for Dales mutants
to the isolates described here and accessioned by the
ATCC, thus eliminating any further discrepancies in the
literature.
There are some discrepancies between the collection
as described by Dales et al. (1978) and the collection that
we obtained from the ATCC. These discrepancies are
illustrated in Tables 2–5. Specifically, Dales et al. pub-
lished the isolation of 93 viruses, of which 79 were
characterized by electron microscopy (Tables 1–6). We
received 97 viruses that were deposited by Dales with
the ATCC (Tables 2–4, Dts1–Dts97). Of the 93 viruses
described by Dales, 23 were missing from the ATCC
collection (Table 5). Twenty-seven of the 97 viruses that
we received as the ATCC collection were not previously
described in any form (Tables 2–4, n.d.) and 16 viruses
were published but not categorized by morphology (Ta-
bles 2–5, n.c.). We have characterized the Dales mutants
we received from the ATCC and noted the discrepancies.
All 97 mutants representing the ATCC (Dales) collec-
tion were grown in BSC40 cells at the permissive tem-
perature, 31°C, and assayed for temperature sensitivity
by plaque titration at 31 and 39.5°C. Each mutant was
evaluated for potential fitness in the complementation
assay using two measurements, the reversion index (RI)
and the leakiness titer. The RI of each mutant was cal-
culated by the equation: number of large plaques at
39.5°C/number of plaques at 31°C. The leakiness titer is
defined as the number of small plaques at 39.5°C. The
threshold values for keeping each mutant for comple-
mentation analysis required a RI of 104-105 or lower
and a leakiness titer of 104 or lower. These cutoffs are
based on previous observations that mutants with high
reversion indices may be difficult to grow without a
substantial accumulation of revertants, and mutants with
high values for leakiness or reversion may yield false
positives in the complementation assay (Condit et al.,
1983). For those mutants with a RI on the borderline of
our cutoff, several plaques were isolated and assayed
for temperature sensitivity. In most cases this resulted in
isolation of virus with a low enough RI for further analy-
sis. These mutants are represented by a P under the
column heading “Purified” in Table 2. In an effort to retain
additional mutants that could theoretically represent
unique mutations, we tested 10 mutants originally
deemed too leaky for analysis (leakiness titer of 105 or
higher at 39.5°C). We were unable to draw conclusions
from 8 of the 10 mutants tested due to high backgrounds
in the complementation analysis. We therefore did not
pursue further analysis of mutants that we originally
deemed too leaky. Of the original 97 viruses, 16 were
deemed too leaky for use in the complementation assay
(Table 4).
The assignment of each mutant to a complementation
group was based on the qualitative spot test described
previously by Condit and Motyczka (1981). Since we have
access to the Condit collection, we were in possession
of 32 defined complementation groups of vaccinia virus.
We used at least one representative from each of the 32
Condit groups (Table 6, underlined) for complementation
with the Dales mutants, thus avoiding the tedious work of
performing pairwise infections for all of the Condit mu-
tants. The remaining 81 mutants from the ATCC (Dales)
collection, following analysis of RI and leakiness, were
divided into five sets and tested for complementation. For
each of the five sets, at a minimum, complementation
was tested in pairwise infections with all of the mutants
within the set, at least one representative from each of
Condit’s 32 groups, and a representative from each
complementation group derived from each of the other
four sets of Dales mutants. As final confirmation that all
mutants in a given complementation group were in fact
noncomplementing, pairwise spot tests were performed
with all mutants in each group using a complementing
mutant as a positive control. Examples of complementa-
tion tests performed for the purpose of confirming groups
D5, G2, and U5 are shown in Fig. 1. Group D5 contains
mutants Cts24, Dts12, Dts38, and Dts56 (rows A and B,
Figs. 1a and 1c). Cts15, a mutant in the F10L gene, was
the positive control for complementation in this group.
Group G2 comprises the mutants Cts56, Dts22, and
Dts42 (rows C and D, Figs. 1a and 1c). Cts15, an F10L
mutant, and Cts33, a D13L mutant, were the positive
controls. The unmapped complementation group U5 con-
TABLE 5
Mutants Reported by Dales But Not Deposited With the ATCC
Dales plaque isolate no. Dales categorya
146 n.c.
223 K
293 n.c.
1918 n.c.
2100 n.c.
2926 O
3216 n.c.
4094 H
5879 Q
7126 Q
7343 P
8845 B
9141 G,P
9194 DNAneg,C
9215 B
9223 B
9279 C
9330 C
9391 A
9433 B
9578 B
a n.c.  no category assigned by Dales.
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TABLE 6
Complementation Analysis and Physical Mapping of Vaccinia Mutants
Map
locationa Mutantsb Phenotype/function
Dales
categoryc Referencesd
A1 Cts63 Defective late/VLTF Carpenter and DeLange, 1992
A3 Cts8, Cts26 Normal/p4b core protein S. Kato, N. Moussatche´, R. C.
Condit, unpublished data
A(8–17) Cts40 Normal
A18 Cts4, Cts22, Cts23 Abortive late/ATPase/DNA
helicase/transcript release
factor
Lackner and Condit, 2000
A24 Cts27, Cts29, Cts32, Cts47, Cts62,
Dts60(7672), Dts66(7954), Dts86(9179),
Dts90(9235), Dts10(1131), Dts14(1655),
Dts28(3679), Dts49(7004), Dts52(7160),
Dts94(9283)
Defective late/RNAP (132 kDa)/
IBT resistance n.d., n.c., n.c.,
O, C, (B,P),
(G,P), G, n.c.,
n.d.
Hooda-Dhingra et al., 1990
A(25–29) Cts6, Cts9 Normal
A30 Dts45(6754)?, Dts46(6757)? n.d., F Szajner et al., 2001
B1 Cts2*, Cts3, Cts25*, Dts15(1911) DNA neg./protein kinase N Rempel and Traktman, 1992;
Kovacs et al., 2001
D2 Ets52, Ets94 Normal/virion core Dyster and Niles, 1991
D3 Cts5, Cts35 Normal/virion core Dyster and Niles, 1991)
D4 Dts27(3578), Dts30(4149)* DNA neg./uracil DNA
glycosylase
n.d., B Millns et al., 1994
D5 Cts17*, Cts24*, Ets69, Dts12(1408),
Dts38(6389)*, Dts56(7473)
DNA neg. n.d., C, n.d. McFadden and Dales, 1980;
Evans and Traktman, 1992
D6 Cts46, Ets93 Normal/VETF subunit Li et al., 1994
D7 Cts21, Ets45 Defective late/RNAP (18 kDa) Seto et al., 1987
D11 Cts36, Cts50, Ets17 Defective late/ATPase/NPH-I Christen et al., 1998
D12 Dts96(9383) VTF and capping enzyme
subunit/VITF
(E,Q) Carpenter and DeLange, 1991
D13 Cts33, Cts43, Ets101, Dts9(1085), Dts62(7743),
Dts88(9203)
Normal/rifampicin resistance/
virion structure
E, E, E Lake et al., 1979; Seto et al.,
1987
E(2–8)a Cts52, Dts41(6606), Dts80(9021) Normal P, (H,Q)
E(2–8)b Cts19, Dts23(3268), Dts25(3498) Normal n.d., n.d.
E9 Cts42*, NGts26e DNA neg./DNA polymerase/
PAA resistance
Traktman et al., 1989
E11 Cts49, Dts19(2096) Normal/core protein B Wang and Shuman, 1996
F10 Cts12, Cts15, Cts28, Cts54, Cts61, Dts11(1327) Normal/virion protein kinase (G,I) Traktman et al., 1995; Wang
and Shuman, 1995
F(11–17) Cts30, Cts48 Normal
G2 Cts56, G2A, G2B, G2C, G2AS1, G2AS6, G2AS9,
Dts22(3145), Dts42(6626)
Defective late/IBT dependent/
PTEF
n.d., D Black and Condit, 1996;
Condit et al., 1996
G3 Cts60 Normal Meis and Condit, 1991
G(6–8) Cts11, Cts41, Dts45(6754)?, Dts46(6757)?,
Dts68(8490), Dts89(9231)
Normal n.d., F, P, C Meis and Condit, 1991
H4 Cts1, Cts31, Cts55, Cts58 Normal/rap94 Kane and Shuman, 1992
I7 Cts16, Cts34 Normal/virion core Ericsson et al., 1995
I8 Cts10, Cts18, Cts38, Cts39, Cts44, Dts67(8125) Normal/RNA helicase/NPH-II (H,Q) Gross and Shuman, 1996
J1 Cts45 Normal R. C. Condit, unpublished
J4 Cts7, Cts20, Dts44(6741) Defective late/RNAP (22 kDa) B Hooda-Dhingra et al., 1989
J6 Cts51, Cts53, Cts65, Dts85(9174) Defective late/RNAP (147 kDa) C Hooda-Dhingra et al., 1989
U1 Cts57 Normal
U2 Cts37 Normal
U3 Cts13, Cts64 Normal
U4 Dts2(0155) K
U5 Dts4(0260), Dts8(0991), Dts35(5804),
Dts93(9281)
n.d., L, O, n.c.
U6 Dts16(1923), Dts17(1988) P, n.d.
U7 Dts18(2047) P
U8 Dts20(2160), Dts97(9609) P, B
U9 Dts33(5752) P
U10 Dts36(6003), Dts50(7014) n.c., n.d.
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sists of mutants Dts4, Dts8, Dts35, and Dts93 (Figs. 1b
and 1d). Cts63, an A1L mutant, and Cts15, an F10L
mutant, were the positive controls for complementation.
In all cases, the complementation assays demonstrate
the absence of plaques in the presence of two non-
complementing mutants (for example, Cts24 and Dts12,
Figs. 1a and 1c, row A, well 1) and the formation of
plaques when two mutants complement one another (for
example, Cts24 and Cts15, Figs. 1a and 1c, row A, well 4).
The single infection with each mutant was negative, i.e.,
no macroscopic plaques were detected (data not
shown).
During complementation analysis 22 mutants comple-
mented poorly or in an anomalous manner and were
dropped from consideration (Table 3). Table 3 also in-
cludes the eight mutants mentioned above that were
originally deemed too leaky but for which complementa-
tion was nevertheless attempted and which subse-
quently were dropped from further consideration for
anomalies observed during complementation. The final
results of the complementation assays are shown in
Table 6 with the new mutants in each group shown in
bold. The final compilation contains 132 mutants from
three collections, together representing 53 complemen-
tation groups, 32 of which have been mapped or partially
mapped to vaccinia genes and 21 of which are un-
mapped. Each of the complementation groups contain-
ing new mutants is discussed further below.
A24: The 132-kDa RNA polymerase subunit
The members of the A24 group as defined by comple-
mentation and/or marker rescue include five mutants
from the Condit collection (Cts27, Cts29, Cts32, Cts47,
Cts62) and 10 mutants from the Dales collection (Dts10,
Dts14, Dts28, Dts49, Dts52, Dts60, Dts66, Dts86, Dts90,
Dts94) (Table 6). The Condit mutants were previously
mapped by marker rescue to the A24R gene, the 132-kDa
vaccinia RNA polymerase subunit (RNAP) (Thompson
and Condit, 1986; Patel and Pickup, 1989; Hooda-Dhingra
et al., 1990). The A24 group demonstrated some unusual
complementation properties. Previous complementation
analysis with the five Condit mutants revealed that Cts27,
Cts29, Cts32, and Cts47 were noncomplementing in all
pairwise crosses. Cts62 was noncomplementing with
only Cts47 while complementing Cts27, Cts29, and
Cts32. It was concluded that Cts62 underwent intragenic
complementation with the three mutants Cts27, Cts29,
and Cts32 (Hooda-Dhingra et al., 1990). In this study, all
of the Dales mutants were noncomplementing with each
TABLE 6—Continued
Map
locationa Mutantsb Phenotype/function
Dales
categoryc Referencesd
U11 Dts40(6567) P
U12 Dts47(6828) P
U13 Dts48(6937) n.d.
U14 Dts57(7526) H
U15 Dts61(7726) n.d.
U16 Dts71(8643) n.c.
U17 Dts77(8933) (A, K) McFadden and Dales, 1980;
Millns et al., 1994
U18 Dts78(8946) (H, Q)
U19 Dts82(9139) B
U20 Dts83(9153) J
U21 Dts95(9312) n.d.
a A specific letter and number combination indicates that the mutants in this complementation group have been mapped to a specific gene. A letter
and range of numbers in parentheses indicates that the mutants are in the same complementation group but are not mapped to a single open reading
frame; an approximate range is indicated, using gene numbers. The letter U indicates that the mutants are not mapped and the number is arbitrary
to help distinguish the unmapped groups from one another.
b Mutants are listed by the new nomenclature (Dtsxx or Ctsxx) with the four-digit number identification used by Dales shown in parentheses.
Mutants that are underlined were used as a representative of that group in complementation. The mutants shown in bold are new to the
complementation group and are described in this article. Mutants shown in italics indicate viruses that may contain more than one mutation.
c The category for each Dales mutant is listed and corresponds to the order in which they are listed at the left.
d Initial characterization of all Condit mutants is described in Condit and Motyczka (1981), Condit et al. (1983), and Thompson and Condit (1986).
For Condit mutants that have been characterized further, the most recent additional references are provided. Initial characterization of all Dales
mutants described in Dales et al. (1978). For Dales mutants that have been characterized further, a prototypical reference is provided. See text for
additional references.
e Described in Sridhar and Condit (1983).
* DNA negative mutant.
? Unusual complementation, see text.
n.c.  no category assigned by Dales. n.d.  no description available.
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other, a result confirmed in three separate complemen-
tation experiments. Complementation analysis with the
Dales and Condit mutants was slightly more complex.
Three Condit mutants (Cts27, Cts29, Cts47) were used as
representatives and were noncomplementing with one
another and with two Dales mutants, Dts60 and Dts66.
Two other Dales mutants showed selective noncomple-
mentation with the Condit mutants. Dts86 was non-
complementing with both Cts29 and Cts47 but comple-
mented Cts27. Dts90, on the other hand, was noncomple-
menting only with Cts47. These results are not
inconsistent with the results reported for complementa-
tion with the five Condit mutants. The Dales mutants that
complement the Condit mutants may represent addi-
tional cases of intragenic complementation.
We performed marker rescue with all 13 mutants in an
attempt to clarify these complementation discrepancies
(data not shown). Two DNA clones were used for marker
rescue, pWR 112–149 and pTA-A24. The cosmid pWR
112–149 was one of three cosmid clones previously used
to map Cts27, Cts29, and Cts47 to the HindIII A fragment
(Hooda-Dhingra et al., 1990). pTA-A24 contains the pre-
cise open reading frame of A24R. Cts27, Cts29, Dts60,
and Dts66 demonstrated rescue with both pWR 112–149
and pTA-A24 as compared to a no DNA control. Dts90
and Dts94 were also rescued by pWR 112–149 and pTA-
A24; however, both mutants formed small plaques in the
presence of either DNA clone. This may suggest the
presence of a second mutation outside of A24R in these
mutants. The remaining mutants, Cts47, Dts10, Dts14,
Dts28, Dts49, Dts52, and Dts86, were too leaky to be
assessed accurately in the tests performed here. Our
marker rescue results unambiguously support the as-
signment of at least two of the Dales mutants to A24. In
FIG. 1. Qualitative complementation tests. (a) A crystal violet-stained 24-well dish showing results of complementation within Groups D5 and G2.
Complementing mutants Cts15 and Dts33 were included as positive controls. The presence of plaques in a given well indicates that the two mutants
are complementing. The absence of plaques in a well indicates that the two mutants are noncomplementing and are thus in the same
complementation group. (b) Complementation analysis of mutants in the unmapped group U5 including Cts15 and Cts63 as positive controls. (c and
d) A diagram showing, by mutant, which viruses were added to each well on the plates in (a) and (b), respectively. The wells designated with “other
assay” contain viruses used in a complementation assay not described here. The wells containing a slash did not contain any virus.
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addition, results reported here, plus previous results,
support the idea that mutants in this group can display
intragenic complementation.
Previous studies on the five Condit mutants compris-
ing the A24 group revealed a phenotype described as
defective late (described in more detail under Introduc-
tion). This phenotype was heterogeneous as exemplified
by the Condit A24 mutants. Cts29 and Cts47 were
strongly defective late mutants. Neither mutant synthe-
sized late proteins at 40°C and both were impaired in
host and early protein synthesis shutoff. Cts27 and Cts32
demonstrated a weaker phenotype. The synthesis of late
proteins was delayed in Cts27 and Cts32 but the delay
was equivalent at both 31°C and 40°C, as was the
amount of protein synthesis. Cts62 defined yet another
phenotype in this group with normal quantities of late
protein synthesis beginning at the same time at both 31
and 40°C, whereas in a wt infection, late protein synthe-
sis generally begins earlier at 40°C than at 31°C. The
growth phenotype and complementation of the Condit
mutants suggested that the mutations affected biochem-
ically different functions of A24. First, the growth pheno-
type did not correlate with the results of protein synthe-
sis analysis. Both Cts27 and Cts32 grew normally at
31°C but exhibited an impaired pattern of viral protein
synthesis. Cts62, on the other hand, did not grow at 40°C
yet exhibited a normal pattern of protein synthesis. The
heterogeneity in phenotype was accounted for by the
hypothesis that in strongly defective late mutants the
mutation destroys a larger percentage of the RNA poly-
merase activity than in weakly defective late mutants
(Hooda-Dhingra et al., 1990). This heterogeneity of phe-
notype is consistent with the heterogeneous EM pheno-
type of the 10 Dales mutants assigned to this group
(Table 6). The Dales mutants assigned to the A24R gene
include diverse morphological phenotypes ranging from
categories B to Q (Tables 1 and 6). As demonstrated by
other Dales mutants (Lake et al., 1979; McFadden and
Dales, 1980), mutants with similar morphological pheno-
types are not necessarily closely related genetically.
The only Dales mutant in this group for which a protein
synthesis phenotype has been described, Dts86, ex-
pressed both early and late functions very slowly, con-
sistent with the assignment of this mutant, and therefore
the rest of the complementation group, to the A24 group
(Wilton and Dales, 1989). Dts86 was also analyzed for its
affect on migration of cellular RNA polymerase II (RNA-
PII). Silver et al. (1979) had reported that host RNAPII
migrated to the cytoplasm during a vaccinia infection and
that in a Dts86 infection this transfer did not occur (Wilton
and Dales, 1989). It was concluded that the migration of
RNAPII may be influenced by overall rates of vaccinia
virus specific synthesis and that absence of RNAPII in
the cytoplasm of a Dts86 infection was a result of de-
layed early synthesis.
An additional mutant from the Dales collection, Dts91,
was dropped during complementation for an even more
complicated complementation phenotype (Table 3).
Dts91 was noncomplementing with Dts90 but comple-
mented the other nine Dales mutants in this group. The
mutant was not tested against the Condit mutants. Dts91
was particularly interesting since it was the only mutant
from 11 tested mutants that had a restriction fragment
length polymorphism associated with the ts locus (Mc-
Fadden et al., 1980). This mutant acquired a novel EcoRI-
restriction site in a restriction fragment corresponding to
the EcoRI fragment D of rabbitpox virus, the only EcoRI
restriction map available at the time. The rabbitpox D
fragment had been shown to reside within the HindIII A
fragment (McFadden et al., 1980). Assuming that rabbit-
pox and IHD-W are similar in EcoRI fragment D (Schump-
erli et al., 1980), these results are not inconsistent with
placement of Dts91, as well as the other mutants of this
complementation group, in A24R.
Two-dimensional gel analysis of extracts from cells
infected with Dts91 revealed a 37-kDa protein with an
altered charge as compared to extracts from wt infected
cells (McFadden et al., 1980). Four independent ts re-
vertants of Dts91 were isolated. Three of the four rever-
tants lost the additional EcoRI site found in the mutant
virus and had a 37-kDa protein mobility identical to wt
IHD-W. The fourth revertant retained the mutant restric-
tion pattern but had a 37-kDa protein mobility intermedi-
ate between wt and Dts91. McFadden et al. (1980) con-
cluded that this fourth revertant was an intragenic sup-
pressor containing a second mutation within the same
gene at a different locus. Obviously the 37-kDa protein is
too small to be the 132-kDa RNAP subunit (encoded by
gene A24R); however, the 35-kDa RNAP subunit is close
in location on the genome (gene A29L). Thus one hypoth-
esis which could explain the charge alteration to the
37-kDa protein in Dts91 is that Dts91 contains a mutation
in A29L. This raises several possibilities concerning the
location of the Dts91 mutation. First, the Dts91 mutation
may be in the A29R gene and its noncomplementation
with Dts90 may indicate that Dts90 is a double mutant,
containing both A24R and A29L mutations. Second, the
Dts91 mutant may have more than one mutation, one in
the A24R gene and a second in the A29L gene. Comple-
mentation of this mutant may depend on the location of
the A24R mutation in the second mutant virus. A third
possibility is that the Dts91 mutation affects an activity of
the A24 protein that has previously remained uncharac-
terized. This may involve a protein modification activity
such as a kinase or a glycosylase, thus affecting the
mobility of the 37-kDa protein in an indirect manner.
Dts91 was dropped from our final results due to the
complicated complementation phenotype. For this same
reason, Dts91 is an interesting mutant that poses intrigu-
ing questions.
Dts91 was categorized as a group E mutant in the
Dales EM phenotype scheme (Table 1) (Dales et al.,
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1978). The other group E mutant viruses contain muta-
tions in either gene D12L or D13L. The group E mutants,
in general, demonstrated a defect in membrane self-
assembly and maturation. Dts91, however, behaved
anomalously at 40°C. The morphogenesis of this mutant
was termed “leaky” as both abnormal envelope formation
and the development of mature virions were observed.
However, Dts91 was “tight” in terms of infectivity (as
measured by plaque assay) (Lake et al., 1979). Addition-
ally, this was the only group E mutant with no defect in
the processing of precursor polypeptides (McFadden et
al., 1980). In summary, Dts91 was different from the other
described group E mutants and, in fact, had a leaky
morphology phenotype that may also affect complemen-
tation of this mutant.
The simplest explanation for our results is that all of
the mutants (Dts10, Dts14, Dts28, Dts49, Dts52, Dts60,
Dts66, Dts86, Dts90, and Dts94) contain at least one
mutation in A24R. We therefore chose to assign these
mutants to the A24 complementation group with the
caveat that further use of these mutants requires that the
mutations be accurately mapped to the A24R gene.
B1: A serine/threonine protein kinase
Complementation analysis placed one additional mu-
tant from the Dales collection (Dts15) in the B1 group that
consisted of three mutants from the Condit collection
(Cts2, Cts3, Cts25) (Table 6). B1 is a 300 amino acid
protein that is expressed early during infection. It en-
codes a protein kinase with specificity for serine and
threonine residues and is known to phosphorylate a
vaccinia late transcription factor encoded by the H5R
gene and the ribosomal proteins, Sa and S2 (Rempel and
Traktman, 1992; DeMasi and Traktman, 2000). B1R is
also one of four genes known to have DNA negative ts
mutant phenotypes.
Initial characterization showed that the Condit mutants
Cts2 and Cts25 were DNA negative as evidenced by the
absence of incorporation of [3H]thymidine into acid-pre-
cipitable material. Interestingly, Cts3 was not DNA neg-
ative in this assay (Condit and Motyczka, 1981; Condit et
al., 1983). Further analysis of Cts3 was not performed
because it could not be mapped by marker rescue and
was thought to contain two mutations (Rempel et al.,
1990). Subsequently, Rempel et al. (1990) analyzed both
Cts2 and Cts25 for DNA replication in mouse L cells and
BSC40 cells. It was found that both mutants displayed a
host range where the restriction on DNA replication was
10-fold more severe and the restriction on viral yield was
20- to 135-fold more complete in L cells than BSC40
cells. The two mutants exhibited different plaque pheno-
types on BSC40 cells. Cts25 produced no macroscopic
plaques where Cts2 produced minute plaques on BSC40
cells at 39.5°C. Both mutants produced unstable B1
proteins; however, the Cts2 B1 protein was unstable at
both temperatures, whereas the Cts25 B1 protein was
specifically unstable at the nonpermissive temperature.
Kovacs et al. (2001) found that Cts25 also had a ts defect
in intermediate gene expression independent of the ef-
fects on viral DNA replication. This is consistent with the
fact that Cts25 directed synthesis of up to 60% of wt DNA
levels but only 15% of viable progeny and no plaques on
BSC40 cells (Kovacs et al., 2001).
Dts15 is the only mutant categorized as group N of the
Dales morphological aberrations (Table 1) (Dales et al.,
1978). Using electron microscopy, this mutant was
shown to produce factories that contained immature and
numerous intermediate maturing forms of virus. This
mutant was classified by Dales as DNA positive using
[3H]thymidine pulse labeling. This method is considered
to be the most stringent since it only measures DNA
synthesis activity during isolated periods (5 h into rep-
lication) of infection (Rempel et al., 1990). It is perhaps
possible that the DNA negativity of this mutant was
missed due to the stringent assay used for characteriza-
tion. However, the DNA negative mutants defined by
Dales were all characterized in groups A–D and the
grouping of this mutant in group N seems to argue that
this mutant is not DNA negative. In summary, the phe-
notypes of mutants in the B1 group are heterogeneous,
even with respect to DNA replication. This may reflect a
multifunctional role for the B1 kinase in virus infection.
Nevertheless, attempts should be made to map Dts15 to
the B1R open reading frame prior to further analysis.
D4: Uracil DNA glycosylase
The members of the D4 complementation group in-
clude two mutants from the Dales collection (Dts27,
Dts30) (Table 6). The vaccinia virus uracil DNA glycosy-
lase gene D4R was originally identified based on homol-
ogy to the Shope fibroma virus (SFV) uracil DNA glyco-
sylase gene (Stuart et al., 1993). Identification of a tem-
perature-sensitive mutant in D4R was independently
revealed when marker rescue mapped the mutation in
Dts30 to the D4R gene (Millns et al., 1994). A uracil DNA
glycosylase acts at the initial stage of the pathway for
excision repair by catalyzing the hydrolysis of uracil
residues that have been introduced into DNA either
through misincorporation of dUTP or through deamina-
tion of cytosine. This activity was rapidly induced follow-
ing a poxvirus infection, suggesting that the enzyme was
required prior to and during DNA synthesis (Stuart et al.,
1993).
Dts30 was characterized by Dales to reside within the
B group of morphological aberrations (Table 1) (Dales et
al., 1978). At the permissive temperature, Dts30 DNA
replication reaches its peak synthesis several hours later
than wt virus and synthesizes less than 50% of the wt
levels of DNA (McFadden and Dales, 1980; Millns et al.,
1994). At the nonpermissive temperature, Dts30 pro-
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duces very little or an undetectable quantity of DNA and
continues to synthesize the early proteins, classifying the
mutant as DNA negative (Dales et al., 1978; McFadden
and Dales, 1980; Millns et al., 1994). The Dts30 ts muta-
tion, a glycine to arginine substitution, was found to
reside at amino acid 179 close to the active site, histidine
181, of the enzyme (Millns et al., 1994; Ellison et al., 1996).
Our complementation results placed Dts27 within the
same complementation group as Dts30. There is no
published description of this mutant from which to spec-
ulate on its phenotype relative to Dts30.
D5: An ATPase required for DNA replication
The members of the D5 group include two mutants
from the Condit collection (Cts17, Cts24), one mutant
from the Ensinger collection (Ets69), and three mutants
from the Dales collection (Dts12, Dts38, Dts56) (Table 6).
The D5 protein is an ATPase required for DNA replication
in vivo (Evans et al., 1995). In our experiments Cts24 was
used as the Condit collection representative and was
found to be noncomplementing with Dts12, Dts38, and
Dts56 (Figs. 1a and 1c, rows A and B). Evans and Trakt-
man (1992) independently confirmed that Cts17 was non-
complementing with Dts38. Four of these mutants were
characterized as DNA negative, Cts17, Cts24 (Condit and
Motyczka, 1981), Ets69 (Seto et al., 1987), and Dts38
(Dales et al., 1978; McFadden and Dales, 1980). The two
remaining mutants, Dts12 and Dts56, have not been
previously characterized.
The precise role of D5 during infection has not been
established. A shift in temperature from permissive to
nonpermissive in Cts17, Cts24, and Dts38 infections re-
sulted in an abrupt cessation of DNA synthesis also
known as a “fast-stop” phenotype. This provided evi-
dence that these mutants were defective in chain elon-
gation and that the mutation affected a gene product
intimately associated with the replication fork (McFad-
den and Dales, 1980; Evans and Traktman, 1992). D5 has
no homology to known replication proteins or helicases,
but has a motif associated with ATP and GTP binding
found in many nucleotide hydrolases involved in DNA
replication. Purified D5 protein demonstrated ATPase
activity that was not stimulated by any common nucleic
acid cofactor and used all eight ribo- and deoxyribo-
nucleoside triphosphates tested as substrates with the
greatest activity resulting from CTP and TTP (Evans et al.,
1995). Interestingly Cts17, Cts24, and Dts38 all contained
N-terminal lesions in D5R and possessed an unex-
plained defect in homologous recombination and marker
rescue, suggesting that D5 may play a role in both DNA
replication and recombination (Evans and Traktman,
1992). The combination of the fast-stop phenotype and
the link to DNA recombination supports a role for D5 in
the unwinding and/or annealing of DNA strands (Evans
et al., 1995).
D12: The small subunit of the mRNA capping enzyme
and VTF
Dts96 was previously mapped to D12L by Carpenter
and DeLange (1991) (Table 6). D12L encodes both the
small subunit of the mRNA capping enzyme and the early
transcription termination factor, VTF. Dts96 is a group E
mutant characterized by morphology similar to the ef-
fects of rifampicin on a wt infection (Table 1) (Dales et al.,
1978; Lake et al., 1979). At both permissive and nonper-
missive temperatures, there was no delay in DNA repli-
cation or protein synthesis (Carpenter and DeLange,
1991). However, there was a temperature-dependent de-
fect in telomere resolution. Protein analysis revealed that
polypeptides p18.5 and p18 were missing or present in
minute quantities, indicating a defect in posttranslational
cleavage (Lake et al., 1979). This mutant was found to
have a single point mutation located at nucleotide 379 in
gene D12L that is responsible for the temperature-sen-
sitive and telomere resolution phenotypes (Carpenter
and DeLange, 1991). Our complementation analysis did
not reveal any additional mutants in D12L.
D13: The p65 scaffold protein
Members of the D13 group include two mutants from
the Condit collection (Cts33, Cts43), one mutant from the
Ensinger collection (Ets101), and three mutants from the
Dales collection (Dts9, Dts62, Dts88) (Table 6). The D13L
gene encodes a 65-kDa protein, designated p65, that is
thought to function as a scaffold protein for the formation
of viral crescents and immature virions (Sodeik et al.,
1994). The three Dales mutants, Dts9, Dts62, and Dts88,
are members of the group E morphology group (Table 1)
(Dales et al., 1978). A previous report of complementation
among the group E mutants assigned Dts9 and Dts88 to
different complementation groups, contradictory to our
data. However, in the same report Dts62 was found to be
noncomplementing with both Dts9 and Dts88, supporting
the assignment of the three mutants to the same comple-
mentation group (Lake et al., 1979). In addition, Carpen-
ter and DeLange (1991) reported that Dts9, Dts62, Dts88,
and Cts33 are noncomplementing and their marker res-
cue analysis supported the assignment of these four ts
mutants to D13L. Our results confirm that Dts9, Dts62,
and Dts88 are all noncomplementing with one another
as well as the Condit collection representative, Cts33,
further supporting the assignment of these three mutants
to the D13 complementation group.
The antibiotic rifampicin has been shown to inhibit the
maturation of poxviruses at a discrete step in envelope
formation (Moss et al., 1969). In the presence of rifampi-
cin, the membranes associated with the viral factories
are irregularly shaped, and crescents and spherical, im-
mature particles do not form (Grimley et al., 1970). Mutant
viruses that are resistant to rifampicin have been
mapped to the D13L open reading frame (Tartaglia and
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Paoletti, 1985; Baldick and Moss, 1987). The Dales group
E mutants possess a morphological phenotype that mim-
ics the defects seen in the presence of rifampicin. The
mutant defects include the formation of numerous viro-
plasmic foci, each surrounded by flexible envelope seg-
ments and membrane structures that are devoid of “spi-
cules,” similar to the aberrant membranes formed in the
presence of rifampicin (Dales et al., 1978). Two groups
have demonstrated using immunolocalization and elec-
tron microscopy that p65 is localized in viral factories,
specifically to the concave surface of viral crescents
(Vanslyke and Hruby, 1994; Sodeik et al., 1994). In the
presence of rifampicin, p65 is found in unique structures
that are referred to as p65 bodies. The rifampicin bodies,
present only in the presence of rifampicin, contain pre-
cursor membranes that are not labeled with p65 antibod-
ies. After removal of the drug, the rifampicin block is
reversed and p65 antibodies again label viral crescents.
These results suggest that the formation of crescents
requires the association of p65 with the membrane pre-
cursors. Thus, it has been proposed that p65 functions
as an internal scaffold protein (Sodeik et al., 1994).
E(2–8): Two complementation groups
Two mutants from the Condit collection map to the
region between E2 and E8 but complement one another.
These mutants, Cts52 and Cts19, therefore represent two
complementation groups, E(2–8)a and E(2–8)b, that map
to this region but whose exact location is not known
(Condit and Motyczka, 1981; Condit et al., 1983; Thomp-
son and Condit, 1986). We have identified two new Dales
mutants by complementation analysis to add to each of
these groups. Those mutants that are noncomplement-
ing with Cts52 and are thus members of group E(2–8)a
include Dts41 and Dts80 (Table 6). Cts52 was reported to
have a normal protein synthesis phenotype (Condit et al.,
1983). Dts41 was assigned to Dales category of morpho-
logical aberration group P, while Dts80 was assigned to
both H and Q (Table 1). Both Dts41 and Dts80 therefore
produced nearly normal or normal particles by electron
microscopy, consistent with the Cts52 normal phenotype
(Dales et al., 1978). Mutants that did not complement
Cts19 but were complementing with Cts52 include Dts23
and Dts25, thus forming group E(2–8)b (Table 6). Cts19
was also reported to have a normal phenotype (Condit
and Motyczka, 1981). No description of Dts23 or Dts25
has been published.
E11: A core protein
One mutant from the Condit collection (Cts49) was
mapped to the E11 gene and is noncomplementing with
one mutant from the Dales collection (Dts19) (Table 6).
E11 is a 129 amino acid protein that is synthesized late
during infection. The protein was found in deoxycholate
extract of virus cores and the insoluble core fraction but
not the envelope fraction, evidence that E11 is a compo-
nent of the vaccinia core. The mutation in Cts49 has
been mapped as a glycine-to-arginine substitution at
amino acid 66 (Wang and Shuman, 1996). Cts49 has a
normal phenotype with no defect in transcription or post-
translational cleavage (Condit et al., 1983; Wang and
Shuman, 1996). Electron microscopy of Cts49-infected
cells showed normal appearing IMV particles at 40°C
and a lack of aberrant viral structures at either 31 or 40°C
(Wang and Shuman, 1996). This is in contrast to Dts19,
which was assigned to category B of morphological
aberrations (Table 1). Cells infected with Dts19 contained
only foci of viroplasm and did not show development of
any membrane structures (Dales et al., 1978). As previ-
ously described for both groups A24 and B1, differences
in the morphology of mutants that are noncomplement-
ing do not preclude the assignment of the viruses to the
same complementation group. Given the discrepancy in
phenotype, however, caution should be taken prior to
analysis of Dts19 to ensure that this mutant maps to E11.
F10: A serine/threonine kinase
The members of the F10 complementation group in-
clude five mutants from the Condit collection (Cts12,
Cts15, Cts28, Cts54, Cts61) and one mutant from the
Dales collection (Dts11) (Table 6). F10L encodes a
serine/threonine kinase that represents the major kinase
activity in the virion. The Condit mutants, Cts15, Cts28,
Cts54, and Cts61, were mapped by marker rescue to the
F10L gene. Cts12, on the other hand, could not be
mapped by either Wang and Shuman (1995) or Traktman
et al. (1995) and was thought to contain one or more
additional mutations located outside of F10L. The four
Condit mutants were found to have normal protein syn-
thesis but varied in the severity of a block in p4a and p4b
processing. Cts61 converts p4b to 4b but does not pro-
cess p4a to 4a. No mature progeny virions were ob-
served at 40°C by electron microscopy in Cts28, Cts54,
and Cts61 infections. Neither Cts15 nor Cts28 demon-
strated signs of virion morphogenesis or spherical im-
mature particles, and in both mutants there was scant
formation of viral membranes (Traktman et al., 1995;
Wang and Shuman, 1995). Reports on Cts54 differ, indi-
cating either that these infections may contain only foci
of viroplasm that are occasionally accompanied by viral
membrane fragments (Wang and Shuman, 1995) or that
these infections contain crescent and immature virions
without nucleoids (Traktman et al., 1995). Cts61 demon-
strated approximately 50% of infected cells that con-
tained sizable virosomes devoid of any virus maturation
and 50% that contained crescents and immature virions
without nucleoids (Traktman et al., 1995; Wang and Shu-
man, 1995). These phenotypes are in agreement with
observed leakiness in a plaque assay: Cts15 and Cts28
did not form macroscopic plaques at 39.5°C and Cts54
250 LACKNER ET AL.
and Cts61 are far leakier, forming minute plaques at
39.5°C (Traktman et al., 1995). Dts11 was categorized in
Dales groups G and I where incomplete membranes with
spicules and some complete immature particles were
observed (Table 1) (Dales et al., 1978). In our hands,
Dts11 was also slightly leaky, scarcely making the cutoff
for useful mutants. The Dts11 phenotype is consistent
with the phenotype described for Cts54 and Cts61.
F10 is expressed late during infection and it is the
major kinase activity in the virion (Wang and Shuman,
1995). A shift in temperature from 39.5 to 32°C in a Cts28
infection resulted in a large burst of Cts28 virus. When
the same temperature shift was performed with the ad-
dition of rifampicin at the time of shift, no burst of virus
was detected. This indicated that arrest in a Cts28 infec-
tion occurs prior to the rifampicin-sensitive step. The F10
mutants therefore define the earliest genetic defined
step in vaccinia virus assembly (Traktman et al., 1995;
Wang and Shuman, 1995). The temperature-sensitive de-
fect in the F10 mutants was proposed to be the result of
failure to phosphorylate one or more viral proteins that
are necessary for membrane formation. Several vaccinia
proteins are phosphorylated in vivo and have been sug-
gested to be the target of F10. These proteins include
F17, H5, and A17 (Traktman et al., 1995; Wang and Shu-
man, 1995; Betakova et al., 1999).
G2: Positive transcription elongation factor
The G2 complementation group includes one original
randomly isolated ts mutant from the Condit collection
(Cts56) and two ts mutants from the Dales collection
(Dts22, Dts42). Additional mutants were created that con-
tain either frameshifting deletions in the G2R gene (G2A,
G2B, G2C) or engineered ts lesions, resulting in the loss
of G2 expression (G2AS1, G2AS6, G2AS9) (Table 6) (Meis
and Condit, 1991; Hassett and Condit, 1994). G2R en-
codes a 26-kDa protein expressed early during infection
that has been proposed to function as a postreplicative
positive transcription elongation factor (Black and Con-
dit, 1996). A complementation test of the G2 mutants is
shown in Figs. 1a and 1c (rows C and D). Cts15 and
Dts33 are used in this experiment as positive controls for
complementation. Clearly, the absence of plaques in
wells 1, 2, and 5 (Figs. 1a and 1c, row C) demonstrates
the lack of complementation between Cts56, Dts22, and
Dts42 as compared to the presence of plaques in row C
wells 3, 4, 6 and row D, wells 1–4 (Figs. 1a and 1c).
Characterization of the G2 mutants Cts56 and G2A
revealed a defective late phenotype (Condit et al., 1983;
Black and Condit, 1996). These viruses synthesize early
viral mRNA, early viral proteins, and viral DNA normally
under nonpermissive conditions. Intermediate and late
viral RNA synthesis begins normally but these mRNAs
are 3 truncated and reduced in amount. This results in
the synthesis of mRNAs that are too short to encode
large late proteins. Base on these results, the G2 protein
was proposed to function as a postreplicative positive
transcription elongation factor, such that in the absence
of G2 protein synthesized transcripts are shorter than in
the presence of G2 protein.
The G2 mutants also demonstrate an altered pheno-
type in the presence of the anti-poxviral drug isatin--
thiosemicarbazone (IBT). In our hands, the differences in
response to IBT have indicated a variation in the activity
of the G2R gene product (Hassett and Condit, 1994).
Viruses that are wild-type for G2 activity are IBT-sensitive
(Fig. 2, IHD-W) and viruses such as G2A, G2B, and G2C,
that have no G2 function, are IBT-dependent (Meis and
Condit, 1991). IBT resistance presumably reflects an in-
termediate level of G2 activity. The IBT phenotype relates
to the G2 mutant phenotype. IBT treatment enhances
transcription elongation (Bayliss and Condit, 1993; Xiang
et al., 1998), compensating for the elongation defect in
G2 null mutants, hence, the IBT-dependent phenotype of
G2 null mutants. The temperature-sensitive mutant Cts56
is IBT-resistant at 31°C, indicating that even at the per-
missive temperature this virus is somewhat compro-
mised for G2 activity. The IBT dependence of Cts56 at
39.5°C reflects the absence of G2 activity at the nonper-
missive temperature (Fig. 2, Cts56) (Meis and Condit,
1991).
Description of the phenotypes of the Dales G2 mutants
includes only Dts42. This mutant was categorized in
Dales group D, mutants that contain foci of DNA viro-
plasm and DNA paracrystals (Table 1) (Dales et al.,
1978). No published description is available for Dts22.
Neither Dts22 nor Dts42 were characterized for tran-
scriptional defects. As further evidence to support the
assignment of Dts22 and Dts42 to the G2 complementa-
tion group, we performed a plaque assay in the presence
and absence of IBT at both 31 and 39.5°C (Fig. 2, Dts22
and Dts42). Under these conditions the phenotype of
both viruses resembled that of Cts56. Specifically, both
Dts22 and Dts42 were IBT-resistant at 31°C and IBT-
dependent at 39.5°C. Thus, the phenotypes of Dts22 and
Dts42 with respect to IBT are consistent with the place-
ment of these mutants in the G2 complementation group.
A30 and G(6–8): A complicated complementation
Our complementation results placed two Condit col-
lection mutants (Cts11, Cts41) and four mutants from the
Dales collection (Dts45, Dts46, Dts68, Dts89) in the same
group (Table 6). All six of these mutants were non-
complementing in three separate complementation
tests. This complementation result is paradoxical be-
cause Dts46 has been mapped to gene A30 (Szajner et
al., 2001), whereas Cts11 and Cts41 have been mapped
to the right half of the HindIII G fragment, comprising
genes G6 through G8 (Meis and Condit, 1991). In an
attempt to resolve this paradox, we performed marker
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rescue of all six mutants using two cosmid clones and
three plasmids covering the regions in question (data not
shown). The cosmids pWR 67–98 and pWR 45–83 were
shown previously to rescue Cts11 and localized the mu-
tation within the region spanning genes G6 to G8
(Thompson and Condit, 1986; Meis and Condit, 1991). We
obtained the plasmids pGEMA30WR, pGEMA30IHDJ,
and pGEMA30TS that were used by Szajner et al. (2001)
to map Dts46 to the A30 gene. These plasmids contain
the A30 gene isolated from wt vaccinia WR, wt vaccinia
IHD-J, and Dts46, respectively. Cts11, Dts68, and Dts89
rescued with pWR 45–83. In addition, Cts11 and Dts89
also rescued with pWR 67–98 (data not shown). These
results are consistent with a map location, as previously
described, in the G fragment. Rescue with Cts41 was
ambiguous, resulting in no convincing mapping result.
Dts45 and Dts46 both rescued with pGEMA30WR and
pGEMA30IHDJ but not with pGEMA30TS, consistent with
a map location in A30 as previously described. To verify
the marker rescue results, we sequenced the A30 gene
in all six viruses (data not shown). Sequencing revealed
that the mutations in Dts45 and Dts46 were identical and
located in amino acid 17, as previously reported for Dts46
(Szajner et al., 2001). The A30 gene from the remaining
four mutants was wt. Although alternate explanations
cannot be ruled out, the simplest interpretation of these
results is that (1) three mutants, Cts11, Dts68, and Dts89,
map to the right-hand side of HindIII fragment G as
previously described for Cts11; (2) Dts45 and Dts46 map
to A30, as previously described for Dts46; and (3) muta-
tions in these two genes are noncomplementing. Aside
from the fact that it does not contain an A30mutation, the
map location of Cts41 is uncertain. We cannot rule out
the possibility that all of these mutants are double mu-
tants. In this case specifically, in addition to G fragment
mutations, Cts11, Dts68, and Dts89 could potentially con-
tain promoter mutations in A30 that went undetected in
our sequence analysis. Likewise, Dts45 and Dts46 could
contain a second mutation in the HindIII G fragment.
However, we consider it unlikely that this would have
occurred in at least four individual mutant isolations;
therefore, we favor the hypothesis that the G fragment
mutants and A30 mutants are noncomplementing.
The EM phenotype of Dts46 makes this mutant very
unique. Dts46 was originally characterized by its over-
production of immature virus envelopes (Dales et al.,
FIG. 2. Plaque formation of select G2 complementation group viruses. Plaque assays were incubated in the presence of 45 M IBT (IBT) or in
the absence of drug (IBT) at 31 and 39.5°C for 7 days and stained with crystal violet.
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1978). These envelopes are unique because they form
separately from the other virus materials concentrated
within the viroplasm and are assembled into multilay-
ered spheres. The spicules that are normally associated
with the adjacent bilayer membrane are disconnected in
the Dts46 mutant. It was proposed that the spicules,
designated p65E, were the product of the D13L gene.
The unusual phenotype of this mutant provided evidence
that under wt conditions the function of the spicules was
to provide a rigid “exoskeleton” that determines the di-
ameter and spherical form of the envelope surrounding
immature virions (Essani et al., 1982; Weinrich et al.,
1985). Cts11 and Cts41 were characterized as showing a
normal phenotype (Condit and Motyczka, 1981; Condit et
al., 1983). This is not inconsistent with the EM phenotype
described for Dts46; however, Cts11 and Cts41 have not
been examined by electron microscopy.
I8: NPH-II
The members of the I8 complementation group in-
clude five mutants from the Condit collection (Cts10,
Cts18, Cts38, Cts39, and Cts44) and one mutant from the
Dales collection (Dts67) (Table 6). I8R encodes the NTP-
dependent RNA helicase, NPH-II. Cts44 may contain
another mutation outside of I8R because, upon marker
rescue, the virus forms plaques that are consistently
smaller than wt or the plaques of the other I8R rescued
mutants. Sequencing revealed that Cts38 and Cts44 con-
tain the same mutation in I8R (Fathi and Condit, 1991a;
Gross and Shuman, 1996). Our complementation results
indicated that Dts67 was noncomplementing with Cts38
but complemented Cts18 and Cts39. Thus, this is poten-
tially another example of intragenic complementation as
observed in gene A24R and discussed in more detail
below.
I8R encodes the NTP-dependent RNA helicase NPH-II.
NPH-II is one of five NTPases packages in virions, in-
cluding NPH-I, VETF, A18, and the mRNA capping en-
zyme (Bayliss and Condit, 1995; Gross and Shuman,
1996; Yu et al., 1997). The precise function of NPH-II is
not known but it is essential for proper execution of early
transcription by the core RNA polymerase. NPH-II may
either disrupt the RNA–DNA hybrids that form during
transcription or affect the extrusion of transcripts out of
the viral core and into the cytoplasm for translation
(Gross and Shuman, 1996).
The I8R gene is transcribed both early and late pro-
ducing two 5 coterminal transcripts. The longer tran-
script encodes the entire I8R gene, while the 3 end of
the smaller transcript maps to an early transcription
termination signal located within the coding sequence.
Only the large protein has been identified; the hypothet-
ical small protein has never been observed. Three Con-
dit mutants, Cts10, Cts18, and Cts39, contain mutations
within the 5 portion of the gene that would affect both
the large and the (hypothetical) small proteins. Cts38 and
Cts44 contain mutations in the 3 region of the gene that
would only affect the larger protein (Fathi and Condit,
1991a). There are formally two possibilities that could
explain the apparent intragenic complementation within
this group. First, it is possible that Cts38 is in fact a
double mutant containing one mutation in I8R and a
second mutation in another gene. In this case Dts67
might contain a mutation in the second (not I8R) gene
affected in Cts38, thus accounting for its selective non-
complementation with Cts38. We favor the more interest-
ing possibility that Dts67 is displaying intragenic comple-
mentation, implying that the I8R gene product acts as a
multimer or is multifunctional. It is noteworthy in this
regard that Cts38, which is the only mutant of the three
Condit mutants that does not complement Dts67, is also
the only mutant that would affect only the larger of the
two potential I8 proteins.
Cts10, Cts18, Cts39, and Cts44 are all completely de-
fective for growth at 40°C but have normal DNA and
protein synthesis at both 31 and 40°C. Electron micros-
copy of Cts18 and Cts44 indicated that either mutant at
31°C is comparable to a wt infection at 31 or 40°C. At
40°C, all mutant-infected cells contained viroplasm with
numerous clusters of apparently mature particles that
resemble the mutant virions at 31°C. Thus there did not
appear to be a defect in morphogenesis of Cts18 or
Cts44 at the nonpermissive temperature (Fathi and Con-
dit, 1991b). Particle-to-PFU ratios in Cts10 and Cts18 are
higher than wt, indicating that a larger number of the
progeny virions in a mutant infection at 40°C are nonin-
fectious. In addition, the mutants Cts10, Cts18, and Cts39
packaged little or no NPH-II protein during assembly
at 40°C (Gross and Shuman, 1996). Dts67 was charac-
terized in both Dales groups H and Q of morphologi-
cal aberrations (Table 1). Infection with Dts67 appar-
ently resulted in some aberrations such as DNA
paracrystals, aberrant membranes with and without spi-
cules, and immature particles; however, immature and
mature particles of normal appearance were still appar-
ent, not inconsistent with the EM phenotypes of other I8
mutants.
J4: The 22-kDa RNAP subunit
The members of the J4 complementation group in-
clude two mutants from the Condit collection (Cts7,
Cts20) and one mutant from the Dales collection (Dts44)
(Table 6). The J4R gene encodes the 22-kDa subunit of
the vaccinia RNA polymerase (Thompson et al., 1989).
Cts7 and Cts20, similar to mutants in other RNA poly-
merase subunits (A24 and J6), were characterized as
defective late. At 40°C these mutants do not shut off
early protein synthesis and are defective in late gene
expression (Condit and Motyczka, 1981; Condit et al.,
1983).
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The EM phenotype of Cts7 was examined at 31 and
40°C. At 31°C, the mutant infection was comparable to a
wt infection. At 40°C, every cell contained at least one
inclusion of viroplasm that was fairly uniform in density
and lighter than the surrounding cytoplasm. These re-
gions were devoid of cellular organelles and viral mem-
branes or particles at any stage of maturation. Some
membranes were present that did not appear to be viral
membranes (Hooda-Dhingra et al., 1989). The EM phe-
notype of RNA polymerase mutants, in general, shows
the formation of large virosomes and no membrane
structures and is consistent with a virus that is capable
of replicating DNA but does not synthesize late viral
proteins. The EM phenotype of Dts44 described by Dales
is analogous to Cts7. Dts44 was characterized as group
B mutants that produce foci of viroplasm at 40°C (Table
1) (Dales et al., 1978). Thus, EM data are consistent with
the complementation analysis. The phenotypes of the J4
mutants are similar to that of Cts53, a ts mutant in J6, the
147-kDa RNAP subunit.
J6: The 147-kDa subunit of the RNAP
The J6 mutants include three from the Condit collec-
tion (Cts51, Cts53, Cts65) and one from Dales collection
(Dts85) (Table 6). J6R encodes the 147-kDa subunit of the
viral RNA polymerase. Protein synthesis of each of the
three Condit mutants demonstrated that Cts53 and Cts65
were strongly defective late at 40°C, and they synthe-
sized little to no late transcripts at 40°C. Cts51, on the
other hand, was “slightly” defective late in that the virus
synthesized wt levels of late transcripts delayed by 2 to
4 h (Hooda-Dhingra et al., 1989). This heterogeneity in
phenotype is similar to mutants in A24R, the 132-kDa
RNAP subunit.
Cells infected with Cts51 and Cts53 were examined by
electron microscopy. At 31°C, both viruses possessed a
phenotype comparable to wt. In Cts53 infections at 40°C,
virtually every cell contained at least one inclusion of
viroplasm, similar to the J4 mutant, Cts7. The inclusions
contained some membranes that did not appear to be
viral membranes. Cts51 infections at 40°C revealed vi-
roplasmic inclusions that contained immature particles.
These inclusions contained large, dense masses of viral
nucleoprotein in close association with immature viral
membranes. These structures are not evident in Cts53
infections, nor are they found in wt infections, consistent
with a leakier phenotype that allows some late protein
synthesis and morphogenesis (Hooda-Dhingra et al.,
1989). Dts85 was characterized by group C with the
presence of rudimentary virus membranes containing
spicules located in foci of viroplasm (Table 1) (Dales et
al., 1978). This phenotype is in agreement with the EM
phenotype described for Cts51 and Cts53.
Unmapped complementation groups
Twenty-eight mutants comprising 21 complementation
groups have not been mapped to a region or gene in the
vaccinia virus genome. These mutants are identified in
the map location column beginning with the letter U,
indicating that the group remains unmapped, followed by
an arbitrary number to help distinguish the groups from
one another (Table 6). There is little information on most
of these mutants other than their morphological pheno-
type. As demonstrated both by us and by other groups,
the morphological phenotype does not necessarily pro-
vide clues to the genetic location of the mutation but is
informative nonetheless.
Group U5 consists of four mutants from the Dales
collection, Dts4, Dts8, Dts35, and Dts93. Complementa-
tion of the mutants in this group with Cts63 and Cts15 as
positive controls is shown in Figs. 1b and 1d. The lack of
complementation between Dts4, Dts8, Dts35, and Dts93
is demonstrated by the absence of plaques in row A,
wells 5 and 6, row B, wells 1, 4, and 5, and row C well 2
(Figs. 1b and 1d). No description is available for Dts4 and
no category of morphology was indicated for Dts93. The
EM phenotype of a Dts8 infection describes immature
particles with nucleoids and defective membranes with
spicules (group L) (Table 1). A Dts35 infection is charac-
terized by immature normal particles and mature parti-
cles with aberrant cores (group O) (Table 1) (Dales et al.,
1978).
Group U6 contains two mutants, only one of which
was previously characterized. Dts16 was categorized as
demonstrating immature normal particles and mature
particles with cores that are predominantly transparent
at the centers (group P) (Table 1). It was hypothesized
that the transparent cores represented the absence of
DNA and nucleoproteins (Dales et al., 1978).
The two mutants representing group U8 were charac-
terized by extreme opposite EM phenotypes (Table 1).
Dts97 produced only foci of viroplasm (group B). Infection
by Dts20 produced immature normal particles and ma-
ture particles with transparent cores (group P).
Group U10 is comprised of two previously uncharac-
terized mutants, Dts36 and Dts50. The phenotypes of
these mutants have not been determined.
Dts77 is of particular interest for two reasons: (1) it is
one of only six DNA negative mutants reported by Dales
et al. (1980) and (2) there are discrepancies between our
complementation results, the DNA negative phenotype
as reported by Dales, and the mapping data reported by
Millns et al. (1994). The DNA phenotype suggested that
the defect in Dts77 was in a critical function required
before the onset of DNA synthesis. Results obtained
from the analysis of early viral DNA-binding proteins
indicated that this mutant may be defective in functions
involving early transcription or translation (Dales et al.,
1978; McFadden and Dales, 1980). The DNA-negative
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phenotype is inconsistent with mapping data that placed
Dts77 in the A3L gene (Millns et al., 1994). A3L encodes
the precursor protein p4b that is expressed late during
infection and processed to 4b, one of three major struc-
tural proteins in the virion core. (Millns et al. (1994)
actually refer to the p4b gene as A4L; however, this is
because of sequence differences between the Copen-
hagen and WR strains of vaccinia. We have adhered to
the Copenhagen nomenclature throughout this article.)
The two characterized mutants that map to A3L, Cts8 and
Cts26, were described as having normal gene expres-
sion and DNA synthesis, an appropriate phenotype for a
structural protein mutant (S. Kato, N. Moussatche´, and
R. C. Condit, unpublished observations). In addition, our
complementation results do not support an assignment
of Dts77 to A3 because, in our hands, Dts77 comple-
mented Cts8, the representative from group A3. In an
attempt to address these discrepancies, we analyzed the
DNA synthesis by the Dts77 mutant in a time course from
0 to 24 h postinfection (hpi) (Fig. 3). DNA synthesis by
Dts77 was compared to DNA synthesis by wt WR (not
shown), wt IHD-W, and Cts24 (a DNA negative mutant in
the D5R gene) at 31 and 39.5°C. Infected cell lysates
from each time point (0, 3, 6, 9, 12, 24 hpi) were blotted
onto a nylon membrane in a slot-blot apparatus and a
32P-labeled oligonucleotide mixture was used for hybrid-
ization. In a wt infection (WR and IHD-W), DNA synthesis
was first observed in the 6-h time point and continued
through 24 hpi at both 31 and 39.5°C (Fig. 3, IHD-W). In
a Cts24 infection, DNA synthesis is delayed at 31°C as
compared to wt and absent at 39.5°C (Fig. 3, Cts24). In
the Dts77 infection, DNA synthesis was first observed at
FIG. 3. DNA synthesis in IHD-W, Cts24, and Dts77 infections. BSC40 cell monolayers infected with wt IHD-W, Cts24, and Dts77 at 31 and 39.5°C
harvested at 0, 3, 6, 9, 12, and 24 h postinfection (hpi). The samples were blotted onto a nylon membrane and probed with a virus-specific 32P-labeled
oligonucleotide mixture followed by autoradiography.
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the 9-h time point at both 31 and 39.5°C and continued
for the length of the time course. Therefore, although
DNA synthesis in a Dts77 infection was slightly delayed,
we classify it as a DNA-positive mutant. One possible
explanation for the discrepancy between our results and
those of Dales et al. (1978) and Millns et al. (1994) is that
due to nomenclatural errors the groups may, in fact, be
analyzing different viruses. Since we were unable to
duplicate the complementation results reported by Millns
et al. (1994), we chose to place Dts77 in the group U17 as
an unmapped mutant.
Conclusions
The result of our complementation analysis is the
identification of a renewed source of useful ts mutants in
vaccinia virus. In addition to sorting 30 IHD-W ts mutants
into 13 of Condit’s existing complementation groups and
confirming the previously described grouping of five
Dales mutants in three complementation groups (groups
A30, D4, and D12), we defined 18 new complementation
groups containing 24 IHD-W ts mutant viruses. Given the
abundance of research which has made use of the
established Condit ts mutant collection, the collection
described here, comprising 138 mutants in 53 comple-
mentation groups, enhances and expands this invalu-
able resource for further characterization of new genes
that will lead to a further understanding of a vaccinia
virus infection.
MATERIALS AND METHODS
Eukaryotic cells, viruses, and bacterial hosts
BSC40 cells, a continuous line of African green mon-
key kidney cells, and L929 cells (obtained from ATCC), a
continuous line of murine fibroblast cells, were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum. The temperature-sen-
sitive mutant viruses employed in this study were iso-
lated and characterized previously (Dales et al., 1978;
Condit and Motyczka, 1981; Condit et al., 1983). Wild-type
WR and IHD-W (obtained from S. Dales in 1977) were
initially grown and plaqued on both BSC40 and L929 cells
at 31, 37, and 39.5°C. BSC40 cells were used for subse-
quent growth and titering of vaccinia virus WR and IHD-W
ts mutants. For virological assays of the mutants, incu-
bations were carried out at 31 and 39.5°C, the permis-
sive and nonpermissive temperatures, respectively.
Top10F Escherichia coli comp cells supplied in the Ad-
vanTAge PCR Cloning Kit (Clontech Laboratories, Inc.)
were used for cloning pTA-A24.
Plasmids and cosmids
pGEMA30WR, pGEMA30TS, and pGEMA30IHDJ were
obtained from B. Moss (Szajner et al., 2001). pTA-A24
contains the coding sequence for the vaccinia virus gene
A24R inserted in the pT-Adv vector from the AdvanTAge
PCR Cloning Kit (Clontech Laboratories, Inc.). The gene
was PCR-amplified using gene-specific primers de-
signed against the precise open reading frame of A24R
from wt WR vaccinia virus DNA. Cosmid clones pWR
45–83, pWR 67–98, and pWR 112–149 were described
previously (Thompson and Condit, 1986).
Complementation
Qualitative spot tests for complementation were per-
formed as previously described (Condit and Motyczka,
1981). First, the appropriate amount of virus for use in
complementation was determined by serial dilution in
24-well tissue culture dishes. Threefold dilutions from
102 to 2.43  104 for each mutant virus were tested by
adding two drops of each dilution in a single well of a
24-well tissue culture dish containing confluent BSC40
cell monolayers. The dishes were then incubated at
39.5°C for 3 days and cell monolayers were stained with
crystal violet. The highest concentration of virus that did
not cause damage to the cell monolayer was chosen for
use in complementation tests. Pairwise complementa-
tion assays were performed by the addition of one drop
of the chosen dilution of each mutant virus to a single
well of BSC40 cells growing in a 24-well dish. The dishes
were incubated at 39.5°C for 3 days and stained with
crystal violet. The dishes were then analyzed for the
presence or absence of plaques.
Marker rescue
Marker rescue analysis was performed as a modifica-
tion of the previously described protocol (Thompson and
Condit, 1986). Briefly, 60-mm dishes of BSC40 cell mono-
layers were infected with 0.5 ml of the dilution of mutant
virus used for complementation. Following a 1-h absorp-
tion at 31°C, the inoculum was removed and replaced
with 4 ml 1 DME containing no serum. Infected mono-
layers were incubated at 31°C for 3 h at which time 0.1 ml
Lipofectin (Invitrogen)-complexed DNA was added drop-
wise to the medium. The media was removed the next
day and replaced with 4 ml 1 DME containing 10% fetal
calf serum. The infected/transfected monolayers were
then incubated at 39.5°C for an additional 3 days. On the
fourth day of infection cell monolayers were stained with
crystal violet and analyzed for the presence or absence
of plaques.
Preparation of vaccinia virus DNA
Wt vaccinia WR DNA was purified from twenty 150-mm
dishes of infected BSC40 cells as previously described
with modifications (Esposito et al., 1981). Infected cells
were scraped from the dishes, collected by centrifuga-
tion, and resuspended in 40 ml isotonic buffer (10 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA). The cells
were collected by centrifugation at 2000 rpm, resus-
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pended in 18 ml hypotonic buffer (10 mM Tris–HCl, pH
8.0, 10 mM KCl, 5 mM EDTA), and incubated on ice for 10
min. The plasma and outer viral membranes were dis-
solved with the addition of 50 l -mercaptoethanol and
2 ml 10% Triton X-100 and incubation on ice for 10 min.
The cell debris was removed by centrifugation at 2000
rpm for 5 min. The supernatant was centrifuged for an
additional 5 min and the supernatant was removed. Viral
cores were pelleted from the remaining supernatant by
centrifugation at 9000 rpm. The pellet was resuspended
in 9 ml TE (10 mM Tris–HCl, 1 mM EDTA), 30 l -mer-
captoethanol, 100 l proteinase K, 400 l 5 M NaCl, and
1 ml 10% SDS was added, and the solution was incu-
bated for 60 min at 37°C. DNA was extracted twice with
an equal volume of STE (0.1 M NaCl, 0.05 M Tris–HCl, pH
7.4, 0.001 M EDTA)-saturated phenol/chloroform followed
by precipitation with 2.5 vol ethanol. The snarl of ethanol-
precipitated DNA was picked from solution with the tip of
a heat-sealed Pasteur pipet. The DNA was washed by
swirling in a tube of 70% EtOH. The pellet was air-dried,
resuspended in 0.2 ml TE (10 mM Tris–HCl, pH 7.4, 1 mM
EDTA), and stored at 4°C.
Total cellular plus viral DNA from temperature-sensi-
tive mutant viruses and wt IHD-W was prepared from 0.2
ml infected cell lysate using the QIAamp DNA mini kit
(Qiagen) and resuspended in 200 l Buffer AE (Qiagen).
DNA synthesis
Analysis of DNA synthesis was based on previously
described protocols (Ausebel et al., 1994; Cassetti et al.,
1998; Punjabi et al., 2001). Monolayers of BSC40 cells in
35-mm dishes were infected with the appropriate virus at
an m.o.i. of 10 and adsorbed for 30 min at either 31 or
39.5°C. The virus was then removed and replaced with
1 DME containing 10% fetal calf serum and returned to
the appropriate temperature. The dishes of infected cells
were incubated at either 31 or 39.5°C for 0, 3, 6, 9, 12, or
24 h postinfection. At each time point the cells were
harvested, washed with PBS (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 2 mM KH2PO4), suspended in 300 l
loading buffer (10 SSC, 1 M ammonium acetate (1
SSC is 0.15 M NaCl, 0.015 M Na-citrate)), and stored at
70°C until all samples were collected. Cells were lysed
by three cycles of freeze-thaw and the samples were
subsequently diluted with the addition of 450 l loading
buffer.
Samples were applied to a nylon membrane (Nytran N,
Schleicher & Schuell) in a vacuum manifold (slot-blot
apparatus, Schleicher & Schuell). The membrane was
blotted three times on 3 MM Whatman paper saturated
with 0.5 N NaOH, three times on paper saturated with 1
M Tris–Cl, pH 7.5–1.5 M NaCl, and finally three times on
paper saturated with 2 SSC. The DNA was crosslinked
to the membrane with a Stratalinker 2400 (Stratagene),
sealed in a bag, and stored at 20°C until further use.
The probe used for DNA hybridization consisted of a
mixture of 13 virus-specific oligonucleotides that were
antisense to various regions of the F17R, K1L, K2L, and
A10L genes (oligo mix). The probe was 5-end labeled
with [32P]ATP using T4 kinase (New England Biolabs).
Unincorporated nucleotides were removed using a Nuc-
trap column (Stratagene).
Hybridization was carried out at 42°C using the pro-
tocol described by Ausebel et al. (1994) with slight mod-
ifications. The prehybridization and hybridization solu-
tions contained 6 SSC, 0.1% SDS, 10 Denhardt’s (50
Denhardt’s is 1% (w/v) Ficoll 400, 1% (w/v) bovine serum
albumin (Sigma, Fraction V), and 1% (w/v) polyvinylpyrro-
lidone), and 100 g single-stranded Salmon sperm DNA.
After hybridization, the membrane was washed in 5
SSC, 0.1% SDS once at room temperature and twice at
50°C for 20 min each, blotted dry, and exposed to X-ray
film.
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